Alexander Kamb, PhD, A2 Biotherapeutics, Agoura Hills, CA, talks on the potential of cell therapies for solid tumors. Cell therapies have many advantages compared to other treatment strategies, and there is still a lot of room for improvement. Dr Kamb explains that A2 Biotherapeutics is focusing on developing a receptor system that exploits common losses of genetic material in tumor cells to selectively kill these cells using known targets for cell therapy that haven’t been successful due to high toxicity. In addition, research is also currently investigating strategies to improve cell persistence and cell survival at the tumor site. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
